Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Quell® Fills Unmet Need for Chronic Knee Pain Relief that is Drug-Free
WOBURN, Mass. , Aug. 10, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq: NURO) published an infographic on chronic knee pain ( available here ) and provided an update on how Quell technology addresses knee pain. One-quarter of U.S. adults suffer from frequent knee pain, which decreases
View HTML
Toggle Summary NeuroMetrix Reports Q2 2020 Financial Results
WOBURN, Mass. , July 23, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended June 30, 2020 . The Company is a leading developer of neurostimulation-based medical devices that are used to diagnose and treat chronic health
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for Second Quarter 2020 Financial Results Conference Call
WOBURN, Mass. , July 16, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 second quarter financial results before the opening of the market on Thursday, July 23, 2020 . The Company will host a conference call at 8:00 a.m., Eastern Time on July
View HTML
Toggle Summary NeuroMetrix Reports DPNCheck® Expansion in China
WOBURN, Mass. , July 09, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced expanded distribution in China for DPNCheck, a fast, accurate and quantitative nerve conduction test for evaluation of peripheral neuropathies such as diabetic peripheral neuropathy (DPN).
View HTML
Toggle Summary NeuroMetrix Signs DPNCheck® Collaboration Agreement with Biomedix
WOBURN, Mass. , June 25, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it has signed a collaboration agreement with Biomedix to comarket DPNCheck for peripheral neuropathy detection within Medicare Advantage and other value-based care markets.
View HTML
Toggle Summary NeuroMetrix to Target Chronic Knee Pain with Quell® 2.0 Wearable Pain Relief Device
WOBURN, Mass. , June 10, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq: NURO) today announced that it has launched a marketing initiative focusing on chronic knee pain.  This effort includes direct-to-consumer digital marketing as well as informing physicians and other health care providers
View HTML
Toggle Summary NeuroMetrix Reports Q1 2020 Financial Results
WOBURN, Mass. , April 23, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2020 .  The Company is a leading developer of neurostimulation-based medical devices that are used to diagnose and treat chronic
View HTML
Toggle Summary NeuroMetrix Reports Quell® Technology to be Used in NIH-Funded Trial Evaluating Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS) for Fibromyalgia
WOBURN, Mass. , April 16, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that Quell technology has been selected for use in a large, NIH -funded, randomized, pragmatic clinical trial of TENS for fibromyalgia.   Fibromyalgia is a disorder characterized by widespread
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for First Quarter 2020 Financial Results Conference Call
WOBURN, Mass. , April 16, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 first quarter financial results before the opening of the market on Thursday, April 23, 2020 . The Company will host a conference call at 8:00 a.m., Eastern Time on
View HTML
Toggle Summary NeuroMetrix Announces 2020 Annual Meeting of Shareholders Will Be Held in Virtual Meeting Format Only
WOBURN, Mass. , April 10, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that, due to the public health impact of the COVID-19 pandemic and in accordance with orders issued by the Governor of the Commonwealth of Massachusetts , the Company’s 2020 Annual Meeting of
View HTML